ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Terns Announces Positive Interim Results from Ongoing Trial of TERN-201
August 14, 2019Terns Pharmaceuticals announced the interim results of an ongoing Phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, being developed for the treatment of NASH. -
Terns to commercialise GENFIT’s elafibranor to treat NASH and PBC
June 27, 2019Terns Pharmaceuticals has signed an agreement to acquire the exclusive rights to develop, register and market GENFIT’s elafibranor. -
Terns Acquires Rights to Develop, Commercialize Three NASH Assets from Lilly
April 09, 2018Terns Pharmaceuticals has signed a global, exclusive license agreement with Eli Lilly and Company to develop, manufacture and commercialize three small molecule therapeutic candidates
Pharma Sources Insight January 2025
